Fulgent Genetics (FLGT) Q2 2026 Earnings Call Transcript

Fulgent Genetics reported Q2 revenue of $85.4M (+4% YoY, +20% sequential) but warned that a billing/revenue cycle management system transition suppressed collections and drove a guidance cut. Full-year 2026 revenue was revised to $330M–$340M from $350M, and non-GAAP EPS is now a loss of $2.22–$2.35 per share; adjusted EBITDA remains negative at about a $17.1M loss. Offsetting items include integration of Bako Diagnostics/StrataDX, a larger anatomic pathology footprint (+33% YoY; +50% sequential), and continued progress in therapeutics with FDA Phase II meeting completion for FID-007 and Phase I dose escalation completed for FID-022.

Analysis

This looks like a revenue-quality problem, not a demand problem. When a diagnostics company misses because claims are not flowing cleanly through the system, the market should punish the multiple more than the near-term EPS—because the same operational friction tends to linger for several quarters and creates a credibility discount around guidance. The biggest second-order loser is the core lab franchise: once a hospital or reference customer moves work in-house, the lost volume is usually sticky and can expose how much of the remaining base was dependent on a handful of accounts.

The acquisition story is doing real work here, but it also muddies the signal. Integrated pathology assets can mask organic softness for a few quarters, yet they rarely fix reimbursement leakage; meanwhile, larger diagnostics peers with stronger RCM infrastructure and deeper payer contracting capability can quietly take share if customers view FLGT as operationally noisier. On the supply side, this also argues for more cautious sentiment on small-cap specialty lab consolidators generally, because the market may start to extrapolate billing-transition risk across the peer group.

The important catalyst window is the next 1-3 months, not the long-dated oncology pipeline. If collections normalize quickly, the stock can rerate on a cleaner Q3 print; if not, the risk is another guide-down or margin disappointment that overwhelms any clinical optimism. The delayed tax refund is a liquidity cushion, but until it is in hand it should not be treated as available dry powder for buybacks or strategic optionality.

Contrarian view: consensus may be underestimating how much of the recent weakness is self-inflicted and therefore reversible, which creates bounce potential on any evidence the billing fixes are actually deployed. But the flip side is that the market may still be underpricing how hard it is to regain historical collection rates after a systems change, especially when a large customer is simultaneously exiting and the company is still burning cash at the operating level.

Key Decisions for Investors

• Short FLGT on strength over the next 1-2 weeks; use any post-earnings relief rally to build size. Base case is another 10-20% downside if Q3 collection-rate commentary stays vague; thesis breaks if management shows a clear path back to historical collection rates by the next print.
• Pair trade: long DGX or LH / short FLGT for the next 1-3 months to isolate execution risk in specialty diagnostics. The long leg benefits from scale and steadier reimbursement, while FLGT carries idiosyncratic billing and customer-concentration risk.
• Watchlist only on FLGT common if it trades below the level implied by a normalized gross margin trajectory; otherwise prefer puts or a small tactical short because pipeline headlines can create squeeze risk. Reassess if gross margin recovers sequentially without a matching revenue rebound.
• Do not express the thesis through the therapeutic pipeline until the FDA meeting and Phase III timing are de-risked; the stock's near-term driver is still lab operations, not oncology optionality.
• Set an alert for the next quarter's collection-rate disclosure and cash conversion. A sustained improvement there would falsify the short thesis; another guide-down would likely force further multiple compression.